Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Phase 2 Recruiting 21 enrolled Aadi Bioscience, Inc.

NaSingle-groupOpen-labelTreatment

Summary

A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors

Timeline

Start: 2023-11-07
Primary completion: 2025-05-09
Completion: 2025-12-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	nab-sirolimus	Unknown	—	Intravenous

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Summary

Timeline

Drugs

Indications